Advertisement

Archives of Gynecology and Obstetrics

, Volume 284, Issue 2, pp 467–476 | Cite as

Inhibin-βA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation?

  • Ioannis MylonasEmail author
Gynecologic Oncology

Abstract

Introduction

Inhibins and activins are secreted polypeptides of the transforming growth factor-β superfamily that comprise a subfamily of dimeric, disulphide-linked proteins. Inhibins are composed of an alpha subunit and one of two possible beta subunits (βA or βB), while activins are homodimers of the beta subunits. Both inhibins and activins play substantial roles in human reproduction and endocrine-responsive tumors. However, the prognostic significance and clinical implications of inhibin-βA subunits in uterine endometrioid adenocarcinomas have not been defined.

Methods

A series of 229 uterine endometrioid adenocarcinomas from a previously well-characterized cohort were re-evaluated for expression of the inhibin-βA subunit and correlated with several clinicopathological characteristics and clinical outcomes. Both staining intensity and analyses of a semi-quantitative score were used to evaluate inhibin-βA immunolabeling.

Results

The inhibin-βA subunit was present in malignant endometrioid uterine tissue, and was associated with myometrial invasion (p < 0.05). Univariate survival analysis demonstrated no differences in progression-free survival, cause-specific survival and overall survival for inhibin-βA using the median of the calculated semi-quantitative score. However, patients with a positive inhibin-βA, as identified by staining intensity, demonstrated significantly worse cause-specific survival (p < 0.05).

Conclusions

Evaluation of staining intensity revealed better cause-specific survival in patients with negative or low inhibin-βA immunolabeling intensity. Therefore, although of some use, semi-quantification of immunohistochemical reactions might not be definitive for evaluation of the inhibin-βA subunit as a prognostic marker in endometrial cancer patients. Therefore, staining intensity evaluation should be performed in addition to semi-quantitative analysis. Further research is warranted to elucidate the possible implications of inhibin-βA and endometrial carcinogenesis.

Keywords

Endometrial cancer Endometrioid adenocarcinoma Immunohistochemistry Inhibin-βA Prognosis Survival 

Notes

Acknowledgments

The authors would like to thank Dr. S. Worbs, Dr. N. Shabani, Mrs. C. Kuhn, Mrs. S. Kunze, Mrs. S. Schulze, Dr. D. Dian, Dr. A. Gingelmaier, Dr. C. Schindlbeck, Dr. A. Brüning, Dr. U. Jeschke, Prof. H. Sommer and Prof. K. Friese for their help in conducting the primary study. Additionally, he would like to thank Prof. D. Hölzel; Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-University Munich and Mr. M. Schmidt of the Munich Tumor Registry for supplying the survival data. This study was partially supported by the FöFoLe program of the Ludwig-Maximilians-University Munich (297/03), the Friedrich-Baur-Institute Munich and the Weigland Stipendium Program of the Ludwig-Maximilians-University Munich for I. Mylonas. I. Mylonas is founded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG BR 3641/3-1).

Conflict of interest

The author declares that he has no competing interests and no conflicts of interest. He received a lecture fee in the year 2006 with the title “Endometrial cancer and inhibin subunits”. The author does not have any financial, personal, political, intellectual or religious interests in publishing this article.

References

  1. 1.
    Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRefGoogle Scholar
  2. 2.
    Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35:649–662PubMedCrossRefGoogle Scholar
  3. 3.
    Jereczek-Fossa B, Badzio A, Jassem J (1999) Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J Gynecol Cancer 9:285–294PubMedCrossRefGoogle Scholar
  4. 4.
    Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S (2004) Activins and inhibins and their signaling. Ann NY Acad Sci 1038:142–147PubMedCrossRefGoogle Scholar
  5. 5.
    Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P et al (1988) Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44:1–34PubMedGoogle Scholar
  6. 6.
    Xia Y, Schneyer AL (2009) The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202:1–12. doi: 10.1677/JOE-08-0549 PubMedCrossRefGoogle Scholar
  7. 7.
    Welt CK (2002) The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction. Curr Opin Obstet Gynecol 14:317–323PubMedCrossRefGoogle Scholar
  8. 8.
    Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocr Rev 22:836–858PubMedCrossRefGoogle Scholar
  9. 9.
    Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Vigano P, Di Blasio AM, Genazzani AR, Vale W (1998) Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 83:1194–1200PubMedCrossRefGoogle Scholar
  10. 10.
    Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45:1304–1314. doi: 10.1016/j.ejca.2009.01.008 PubMedCrossRefGoogle Scholar
  11. 11.
    Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS, Friese K (2004) Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122:461–471PubMedCrossRefGoogle Scholar
  12. 12.
    Worbs S, Shabani N, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K, Mylonas I (2007) Expression of the inhibin/activin subunits (-alpha, -betaA and -betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers. Oncol Rep 17:97–104PubMedGoogle Scholar
  13. 13.
    Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V, Friese K (2004) Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 93:92–97PubMedCrossRefGoogle Scholar
  14. 14.
    Risbridger GP, Ball EM, Wang H, Mellor SL, Peehl DM (2004) Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol Cell Endocrinol 225:73–76PubMedCrossRefGoogle Scholar
  15. 15.
    Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, Ogata E, Miyazono K, Shimizu K, Imamura T (2007) Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98:127–133PubMedCrossRefGoogle Scholar
  16. 16.
    Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S (2008) Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 14:660–667PubMedCrossRefGoogle Scholar
  17. 17.
    Deligdisch L, Holinka CF (1987) Endometrial carcinoma: two diseases? Cancer Detect Prev 10:237–246PubMedGoogle Scholar
  18. 18.
    Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17PubMedCrossRefGoogle Scholar
  19. 19.
    Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223PubMedCrossRefGoogle Scholar
  20. 20.
    Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552PubMedCrossRefGoogle Scholar
  21. 21.
    Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I (2007) Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 43:2434–2444. doi: 10.1016/j.ejca.2007.08.014 PubMedCrossRefGoogle Scholar
  22. 22.
    Mylonas I (2010) Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep 24:385–393PubMedCrossRefGoogle Scholar
  23. 23.
    Bassarak N, Blankenstein T, Bruning A, Dian D, Bergauer F, Friese K, Mylonas I (2010) Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer 10:224. doi: 10.1186/1471-2407-10-224 PubMedCrossRefGoogle Scholar
  24. 24.
    Mylonas I (2010) Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: prognostic significance and clinical implications. Eur J Cancer 46:2485–2493. doi: 10.1016/j.ejca.2010.06.001 PubMedCrossRefGoogle Scholar
  25. 25.
    Brüning A, Jückstock JK, Blankenstein T, Makovitzky J, Kunze S, Mylonas I (2010) The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol (in press)Google Scholar
  26. 26.
    Anonymous (1989) FIGO stages (announcements). Gynecol Oncol 35:125–127Google Scholar
  27. 27.
    Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRefGoogle Scholar
  28. 28.
    Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Kunze S, Schulze S, Kainer F, Friese K (2006) Expression of inhibin/activin subunits alpha (-alpha), beta A (-beta (A)) and beta B (-beta (B)) in placental tissue of normal and intrauterine growth restricted (IUGR) pregnancies. J Mol Histol 37:43–52PubMedCrossRefGoogle Scholar
  29. 29.
    Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Schulze S, Kainer F, Friese K (2006) Expression of inhibin/activin subunits alpha (-alpha), betaA (-betaA), and betaB (-betaB) in placental tissue of normal, preeclamptic and HELLP pregnancies. Endocr Pathol 17:19–34PubMedCrossRefGoogle Scholar
  30. 30.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  31. 31.
    Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220Google Scholar
  32. 32.
    Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L (2004) A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 93:34–40PubMedCrossRefGoogle Scholar
  33. 33.
    Kimmich T, Bruning A, Kaufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K, Mylonas I (2010) Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet 282:185–191. doi: 10.1007/s00404-009-1310-y PubMedCrossRefGoogle Scholar
  34. 34.
    Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V, Friese K (2003) Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. Arch Gynecol Obstet 268:142–150. doi: 10.1007/s00404-003-0526-5 PubMedCrossRefGoogle Scholar
  35. 35.
    Mylonas I, Makovitzky J, Fernow A, Richter DU, Jeschke U, Briese V, Gerber B, Friese K (2005) Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps. Arch Gynecol Obstet 272:59–66. doi: 10.1007/s00404-004-0666-2 PubMedCrossRefGoogle Scholar
  36. 36.
    Vogl J, Hoing A, Schulze S, Kuhn C, Wiest I, Shabani N, Jeschke U, Mylonas I, Friese K (2007) Expression of inhibins in the endometrial carcinoma cell line RL-95-2 after stimulation with cortisol and estradiol. Anticancer Res 27:1989–1993PubMedGoogle Scholar
  37. 37.
    Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A (1994) Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91:8817–8821PubMedCrossRefGoogle Scholar
  38. 38.
    Nadji M (2008) Quantitative immunohistochemistry of estrogen receptor in breast cancer: “much ado about nothing!”. Appl Immunohistochem Mol Morphol 16:105–107. doi: 10.1097/PAI.0b013e3181607323 PubMedCrossRefGoogle Scholar
  39. 39.
    Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A (1992) Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313–319PubMedCrossRefGoogle Scholar
  40. 40.
    Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K (2009) Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 7:15. doi: 10.1186/1478-811X-7-15 PubMedGoogle Scholar
  41. 41.
    Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG (2009) Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia 11:388–396PubMedGoogle Scholar
  42. 42.
    Antenos M, Stemler M, Boime I, Woodruff TK (2007) N-linked oligosaccharides direct the differential assembly and secretion of inhibin alpha- and betaA-subunit dimers. Mol Endocrinol 21:1670–1684PubMedCrossRefGoogle Scholar
  43. 43.
    Antenos M, Zhu J, Jetly NM, Woodruff TK (2008) An activin/furin regulatory loop modulates the processing and secretion of inhibin alpha- and betaB-subunit dimers in pituitary gonadotrope cells. J Biol Chem 283:33059–33068. doi: 10.1074/jbc.M804190200 PubMedCrossRefGoogle Scholar
  44. 44.
    Katik I, Mackenzie-Kludas C, Nicholls C, Jiang FX, Zhou S, Li H, Liu JP (2009) Activin inhibits telomerase activity in cancer. Biochem Biophys Res Commun 389:668–672. doi: 10.1016/j.bbrc.2009.09.055 PubMedCrossRefGoogle Scholar
  45. 45.
    Panopoulou E, Murphy C, Rasmussen H, Bagli E, Rofstad EK, Fotsis T (2005) Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res 65:1877–1886PubMedCrossRefGoogle Scholar
  46. 46.
    Di Simone N, Crowley WF Jr, Wang QF, Sluss PM, Schneyer AL (1996) Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137:486–494PubMedCrossRefGoogle Scholar
  47. 47.
    Di Simone N, Hall HA, Welt C, Schneyer AL (1998) Activin regulates betaA-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells. Endocrinology 139:1147–1155PubMedCrossRefGoogle Scholar
  48. 48.
    Di Simone N, Schneyer AL, Caliandro D, Castellani R, Caruso A (2002) Regulation of endometrial adenocarcinoma cell proliferation by activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol 192:187–195PubMedCrossRefGoogle Scholar
  49. 49.
    Phillips DJ, de Kretser DM, Hedger MP (2009) Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev 20:153–164. doi: 10.1016/j.cytogfr.2009.02.007 PubMedCrossRefGoogle Scholar
  50. 50.
    McCarthy SA, Bicknell R (1993) Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 268:23066–23071PubMedGoogle Scholar
  51. 51.
    Weissenbacher T, Bruning A, Kimmich T, Makovitzky J, Gingelmaier A, Mylonas I (2010) Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J Histochem Cytochem 58:751–757. doi: 10.1369/jhc.2010.956185 PubMedCrossRefGoogle Scholar
  52. 52.
    Käufl SD, Kuhn C, Kunze S, Shabani N, Brüning A, Friese K, Mylonas I (2010) Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer Arch Gynecol Obstet. doi: 10.1007/s00404-010-1614-y
  53. 53.
    Gingelmaier A, Bruning A, Kimmich T, Makovitzky J, Bergauer F, Schiessl B, Friese K, Mylonas I (2010) Inhibin/activin-betaE subunit is expressed in normal and pathological human placental tissue including chorionic carcinoma cell lines. Arch Gynecol Obstet. doi: 10.1007/s00404-009-1340-5
  54. 54.
    Bergauer F, Bruning A, Shabani N, Blankenstein T, Juckstock J, Dian D, Mylonas I (2009) Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines. J Mol Histol 40:353–359. doi: 10.1007/s10735-009-9246-x PubMedCrossRefGoogle Scholar
  55. 55.
    Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF (2005) Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 3:50–61Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.1st Department of Obstetrics and GynecologyLudwig-Maximilians-University MunichMunichGermany

Personalised recommendations